Novartis delivered sales growth (cc), significant margin expansion(cc) and strong innovation in Q1; now with a more focused portfolio

Basel, April 23, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Our focus on execution has resulted in a strong operational performance. We have completed the GSK and Lilly transactions and innovation continues to be strong. We had three approvals in Oncology, FDA priority review for LCZ696, Zarxio became the first biosimilar approved under the new pathway in the US and we launched Cosentyx globally. We are on track to deliver our full-year guidance.”

 

  • Continuing operations1 saw sales, core2  …
/by

Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015

April 16, 2015 – AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.

This recognition for technical innovation is the second award for AirFluSal® Forspiro®. In 2011, the device received the Red Dot Product Design Award, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in …

/by

Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg

  • Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis
  • Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services

Holzkirchen, Germany, April 16, 2015 – Sandoz, a Novartis company, today announced the US approval of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.

“Sandoz …

/by